Legato Capital Management LLC Decreases Stake in BrainsWay Ltd. (NASDAQ:BWAY)

Legato Capital Management LLC lessened its stake in BrainsWay Ltd. (NASDAQ:BWAY) by 22.6% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 90,746 shares of the company’s stock after selling 26,466 shares during the quarter. Legato Capital Management LLC owned 0.48% of BrainsWay worth $856,000 as of its most recent filing with the SEC.

Separately, JPMorgan Chase & Co. boosted its stake in shares of BrainsWay by 316.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 14,769 shares of the company’s stock valued at $136,000 after buying an additional 11,221 shares during the period. Institutional investors own 30.11% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and set a $16.00 target price on shares of BrainsWay in a research report on Monday, December 23rd.

BrainsWay Stock Performance

Shares of NASDAQ BWAY opened at $11.02 on Friday. BrainsWay Ltd. has a fifty-two week low of $4.61 and a fifty-two week high of $11.25. The firm has a market capitalization of $207.40 million, a PE ratio of 110.21 and a beta of 1.25. The stock’s 50-day simple moving average is $9.98 and its 200-day simple moving average is $9.19.

BrainsWay (NASDAQ:BWAY) last issued its earnings results on Tuesday, November 12th. The company reported $0.04 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.03. BrainsWay had a return on equity of 3.52% and a net margin of 3.88%. The business had revenue of $10.50 million for the quarter, compared to analyst estimates of $10.07 million. During the same quarter last year, the company earned ($0.01) EPS. On average, sell-side analysts forecast that BrainsWay Ltd. will post 0.08 earnings per share for the current fiscal year.

BrainsWay Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.